Second, Addex Therapeutics has postponed the initiation of a Phase IIb/III clinical trial of dipraglurant, a novel orally available metabotropic glutamate receptor 5 (mGluR5) inhibitor, for PD patients with levodopa-induced dyskinesias [38]. This evidence concerns the gene GRM5 and Parkinson disease.